Skip to main navigation
USA
English
Brazil
Português
Canada
English
Français
Japan
Japanese
Blog
Patient Resources
Investors & Media
Careers
Contact
Our Purpose
Our Commitment to Patients
Rare Disease Day
Supporting Access for Patients
Approved Medicines
Investigational Therapies
Patient/Advocacy Resources
Corporate Sustainability
Charitable Grants and Donations
Our Company
Our Leaders
Our Partners
Contact Us
Our Medicines
Crysvita® (burosumab-twza)
Dojolvi® (triheptanoin)
Mepsevii® (vestronidase alfa—vjbk)
Our Research
Our Science
Our Pipeline
DTX401 for GSDIa
DTX301 for OTC
UX701 for Wilson Disease
UX143 for Osteogenesis Imperfecta
GTX-102 for Angelman Syndrome
UX053 for GSDIII
Our Clinical Trial Transparency Commitment
Our Gene Therapy Platform
Blog
Patient Resources
Investors & Media
Careers
Contact
MENU
Event Details
Bank of America’s 2023 Health Care Conference
May 10, 2023 at 9:20 AM PDT
Listen to webcast
INVESTORS & MEDIA
Press Releases
Events & Presentations
Corporate Governance
Management
Board of Directors
Committee Composition
Corporate Sustainability
SEC Filings
Stock Information
Analyst Coverage
Investor FAQ
Contact Us
SHAREHOLDER TOOLS
Print
Email Alerts
RSS Feeds
You are about to leave the Ultragenyx website.
Do you want to continue?
Return
Continue
